- Elimova, E., Rha, S. Y., Shitara, K., Liu, T., Tabernero, J., Lee, K.-W., Schenker, M., Tebbutt, N. C., Ajani, J. A., Salimin, N., Ku, G. Y., Kim, J. G., Diaz, I. A., Zhang, J., Pietrantonio, F., Bai, L.-Y., Le Sourd, S., Chen, Y., Grim, J. E., … on behalf of the HERIZON-GEA-01 study group. (2026). Zanidatamab + chemotherapy (Ct) ± tislelizumab for first-line (1l) HER2-positive (Her2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (Mgea): Primary analysis from HERIZON-GEA-01. Journal of Clinical Oncology, 44(2_suppl). https://doi.org/10.1200/JCO.2026.44.2_suppl.LBA285 (Meeting abstract)
Zanidatamab + chemotherapy (Ct) ± tislelizumab for first-line (1l) HER2-positive (Her2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (Mgea): Primary analysis from HERIZON-GEA-0
on 15 de juny de 2026
with No hi ha comentaris
Deixa un comentari